Business Wire

MA-EVERBRIDGE,-INC.

23.3.2020 13:02:12 CET | Business Wire | Press release

Share
Everbridge Launches COVID-19 Shield Software-as-a-Service (SaaS) and Rapid Deployment Templates to Protect People and Maintain Operations Amid Pandemic

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced that the company has launched COVID-19 Shield , a new set of Coronavirus Protection Solutions designed to protect the safety of employees and customers, maintain business operations, safeguard supply chains , and reduce costs and liabilities stemming from the impact of the global coronavirus pandemic . Drawing upon 18 years of crisis management experience, Everbridge’s purpose-built packages mitigate the impact of coronavirus by leveraging the company’s industry-leading CEM platform, used by over 5,000 enterprises globally, to help organizations identify their risks, safeguard their workforce, and manage disruptions to their operations and supply chain. Due to the swift spread of the outbreak, Everbridge offers a Rapid Deployment package for governments , businesses, and healthcare entities to implement the COVID-19 Shield solutions in under 48 hours.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200323005134/en/

COVID-19 Shield offers three new out-of-the-box solutions to help organizations. The individual offerings include Know Your Risks through COVID-19 alerts correlated to an organization’s locations. This solution offers pandemic Situation Reports developed from the world’s largest vetted database of risk data, drawn from machine learning analysis of over 22,000 data sources from 175+ countries and validated by a 24/7 team of analysts monitoring local verified sources. The real-time intelligence includes case statistics, travel advisories, closures and supply chain impacts, all automatically correlated to a business’ affected people and assets.

Secondly, COVID-19 Shield offers Protect Your People to manage critical response plans and automate communications with impacted people, responders, leadership and other stakeholders. Protect Your People correlates a specialized Everbridge-developed threat feed on incidences of the coronavirus with the previously visited, last known and expected location of people in order to help businesses understand the risks to their organization and take appropriate actions. It includes out-of-the box coronavirus-tailored messaging templates for health advisories, travel bans, work-at-home directives, and regular wellness checks. Organizations can also establish high-risk Incident Zones and send instructions when anyone enters these areas.

Thirdly, COVID-19 Shield helps Protect Your Operations and Supply Chains by automatically correlating alerts to physical assets including offices and facilities, production plants, suppliers and supply chain routes, in addition to people. Protect Your Operations pinpoints potential impacts to your assets and production resources, as well as to your suppliers and distribution routes, automates initiating standard operating procedures to quickly resolve issues, and generates real-time status reports on key remediation and recovery tasks. Additionally, the offering reduces liability through full audit trails and after-action reporting. By gaining an organization more time and a more complete picture from which to act, Protect Your Operations enables management teams to be more proactive in mitigating the consequences of the coronavirus.

The COVID-19 Shield packages also provide access to the Everbridge Data Sharing Private Network, which enables customers to share information publicly or privately. A business, for example, can share information with local government agencies and healthcare facilities to gain more local situation intelligence and to better coordinate response activities.

“Staying ahead of the coronavirus continues to be a major challenge for governments, businesses and healthcare systems across the globe,” said Claudia Dent, SVP of Product Marketing at Everbridge. “Everbridge works with thousands of organizations to help them protect their people and their operations. In one week alone, our customers sent more than 30 million coronavirus communications using our platform, a testament to the need for accurate and real-time information in a quickly evolving situation.”

“Organizations around the world have found a continuous need for relevant information and insights that are actionable and can be quickly deployed to protect their people, operations and supply chains from the impacts of coronavirus,” said Rebecca Scorzato, Partner at leading specialist risk consultancy, Control Risks . “As the CEM leader for almost 20 years, Everbridge is uniquely positioned to meet this need and to provide highly relevant information to help understand and mitigate the impacts of this global outbreak.”

In recent weeks, Everbridge has launched a series of actions to address the coronavirus, including providing daily updates on its Coronavirus Preparedness Hub , producing preparedness kits from its experience working with customers on previous widespread medical emergencies, hosting webinars with pandemic preparedness experts, and working with customers to make sure their deployments are ready for the increased activity related to the virus.

Everbridge leveraged its deep, global experience with managing critical events to assemble the coronavirus-related resources. The CEM platform reaches over 550 million people across the world while serving leading F500 companies and well as serving cities , states , and entire countries . Everbridge has been selected by eight countries , several states in India, and multiple states in the United States to protect populations.

About Everbridge

Everbridge , Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,000 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 550 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center® , Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 7 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 6 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com , read the company blog , and follow on LinkedIn , Twitter , and Facebook .

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye